ImprimisRx’s Patented Klarity-C 0.1% Cyclosporine Preservative-Free Formulation May Now Be Prescribed By Florida’s 2,000 Optometrists

ImprimisRx announced its Klarity-C preservative-free formulation (0.1% cyclosporine emulsion) may now be prescribed by Florida’s nearly 2,000 optometrists as a result of the Florida Board of Optometry’s recent additions to its Formulary of Topical Ocular Pharmaceutical Agents. 

Klarity-C was recently recognized as a Best of Saturday Sessions presentation at the 2020 ASCRS Annual Meeting in a presentation entitled “Efficacy of Topical 0.1% Cyclosporine in Chondroitin Sulfate Ophthalmic Emulsion in Patients with Dry Eye” (click here to view the abstract). Klarity-C has been one of ImprimisRx’s fastest growing topical formulations.

“Our Klarity-C formulation helps eye care professionals and their patients serve an unmet need in the ophthalmic prescription pharmaceutical marketplace,” John Saharek, President of ImprimisRx, said in a company news release. “Our team looks forward to continuing to help improve the lives of Floridians and patients across the country by providing them with high quality personalized ophthalmic medications, like Klarity-C, at affordable prices – without the need for prior-authorizations, co-pays, deductibles, confusing discount cards or rebates.”

Prescribers interested in Klarity-C or any of the ImprimisRx family of ophthalmic formulations, please click here for more information.